Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Ascentage Pharma Group International ( ($HK:6855) ) has provided an announcement. Ascentage Pharma Group International ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

Jan 23 (Reuters) - Ascentage Pharma (6855.HK), opens new tab said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable ...

Ascentage Pharma Group said its American depositary shares were slated to begin trading on the Nasdaq Global Market on Friday, with its initial public offering priced at $17.25 per ADS.

Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US. Read more here.

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...